MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Press releases

Stay current with the latest press releases from within the industry.

Submit Press Release

A PL Intelligence subscription will allow you to submit press release drafts. Press release drafts are assessed and published by our PL Intelligence team.

Latest Press Releases

Galenix out-licenses drug delivery technologies to DSM Pharmaceutical Products and forms in a strategic alliance

Galenix today announced that it has out-licensed six drug delivery technologies to DSM Pharmaceutical Products, Parsippany, USA. Galenix and DSM have also agreed on a manufacturing alliance, where... more

euroPLX Continues to Lead the Way in Pharma Partnering, Announces 2010 Events

Barcelona's leading pharma partnering event facilitates 23 pre-scheduled business negotiations per company. Three confirmed events for 2010. more

Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of NEUKINE®, biosimilar form of recombinant GCSF

Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of NEUKINE®, biosimilar form of recombinant GCSF. more

Intas Biopharma to pump in Rs 160 cr for dedicated facility for Monoclonal Antibodies (MAbs)

Ahmedabad-based Intas Biopharmaceuticals today said it has signed an MoU with the Gujarat government for setting up a Rs 160 crore facility dedicated to Monoclonal Antibodies (MAbs) at Sanand in... more

Press release search

Search the Pharmalicensing Press Releases by keyword. Alternatively our advanced search allows you to query by therapeutic target and industry sector.
Year Industrial sector
Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

More recent press releases

Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

Surveyed neurologists perceive the efficacy of Merck Serono’s Rebif nearly as equivalent to that of Biogen Idec’s Tysabri, according to a new report from Decision Resources (more)

Vandervoort lauded for aging research

Faculty of Health Sciences professor Tony Vandervoort has won the prestigious Herbert A. de Vries Research Award for 2010 for distinguished research in the field of aging. (more)

Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

Abbott/Eisai’s Humira will achieve blockbuster sales and become the market leader in 2018, according to a new report from Decision Resources (more)

Dr. David Hill receives Frederick G. Banting Award

Dr. David Hill, Scientific Director of the lawson health research Institute has been honoured with the 2009 Federick G. Banting Award for his significant contributions to preventing diabetes in Canada. (more)

Genes not destiny when it comes to heart disease

When it comes to heart disease, lifestyle usually trumps genetics, says noted genetic researcher Dr. Robert Hegele, Heart and Stroke Foundation of Canada Lecturer at the Canadian Cardiovascular Congress 2009. (more)

Biosimilar TuNEX® from Mycenax completes Phase I/II clinical trial in Taiwan, Phase I in Korea

Protein drug development company Mycenax Biotech Inc. (GreTai, Taiwan: 4726) announced today that its rheumatoid arthritis and psoriasis drug TuNEX®, a biosimilar version of etanercept, has successfully completed a Phase I trial in South Korea and Phase I (more)

Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

However, Tnf-Alpha Inhibitors are not immune to competition from Roche’s emerging Il-6 Inhibitor Actemra, according to a new report from Decision Resources

Patient-Flow models will need to take into account that over ten percent of patients sta (more)

Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

Cymbalta is the agent most likely to lose patient share to Savella over the next two years, according to a new report from Decision Resources

Patient-flow models will need to take into account that the highest percentage of patients take Lyrica (more)

Continuing Global Attendance of Premier European Pharma Partnering Event

Fully booked euroPLX 41 Barcelona sees pharma and biotech business developers from 35 countries, many new-comers. (more)

Stiller to be inducted into Medical Halll of Fame

Dr. Calvin Stiller, one of Robarts founders and transplantation pioneer, has been named as one of the 2010 inductees for the Canadian Medical Hall of Fame. (more)

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Biobusiness 2009
Stem Cell USA
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us